Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2A type 1-A (H2AC1) is a core component of the nucleosome, the fundamental unit of chromatin in eukaryotes, encoded by the intronless gene HIST1H2AA[1][3][7]. H2A is one of the four histone types (H2A, H2B, H3, H4) that assemble as an octamer to package approximately 146 base pairs of DNA into nucleosomes, compacts chromatin, and regulates DNA accessibility[1][3][8]. Histone H2A family members play critical roles in facilitating chromatin structure, genome stability, DNA replication, DNA repair, and transcriptional regulation[1][3][8]. Altered histone expression or variant incorporation can influence chromatin dynamics and has been implicated in various diseases, especially cancer[8]. No drugs selectively target this canonical histone protein; instead, clinical efforts focus on enzymes that modify histones globally (such as HDAC, HAT, and methyltransferase inhibitors)[4]. H2A type 1-A is not a receptor, enzyme, or direct drug target, but is fundamentally important for cell viability and gene regulation.
Not applicable for this canonical histone; histone-modifying drugs (like HDAC inhibitors) act indirectly by altering histone post-translational modifications
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2A type 1-A (H2AC1).